GSK: ViiV seeks European approval for new HIV treatment
(CercleFinance.com) - GlaxoSmithKline said that its HIV unit has submitted a new drug application to the European Medicines Agency, seeking approval for an investigational treatment for HIV in adults with few other treatment options.
ViiV Healthcare's application seeks approval of fostemsavir, used in combination with other antiretrovirals, for people with HIV who have been unable to suppress their virus and have few treatment options remaining.
The EMA's Committee for Medicinal Products for Human Use (CHMP) previously granted an accelerated assessment for the drug.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
ViiV Healthcare's application seeks approval of fostemsavir, used in combination with other antiretrovirals, for people with HIV who have been unable to suppress their virus and have few treatment options remaining.
The EMA's Committee for Medicinal Products for Human Use (CHMP) previously granted an accelerated assessment for the drug.
Copyright (c) 2020 CercleFinance.com. All rights reserved.